| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -76,842 | -55,884 |
| Depreciation expense | 235 | 154 |
| Amortization expense | 207 | 132 |
| Share-based compensation expense | 8,160 | 5,625 |
| Net foreign exchange impacts | -10,792 | -11,710 |
| Other income, net | 2,600 | 1,830 |
| Income tax expense | 11 | 10 |
| Decrease/(increase) in trade receivables | -994 | -932 |
| Decrease/(increase) in other current assets | -7,757 | -2,426 |
| Decrease in r&d benefit receivable | -3,851 | -6,343 |
| Decrease in other long-term assets | -3,401 | -14 |
| (decrease)/increase in trade and other payables | -502 | -3,385 |
| Decrease in contract liabilities | -302 | -214 |
| Decrease in operating lease liabilities | -146 | -126 |
| Net cash provided by/(used in) operations | -44,984 | -34,093 |
| Redemption of term deposits | 98,036 | 26,558 |
| Purchase of term deposits | 92,635 | 72,449 |
| Purchase of property, plant and equipment | 55 | 52 |
| Net cash provided by/(used in) investing activities | 5,346 | -45,943 |
| Proceeds from issue of ordinary shares | 15 | 15 |
| Net cash provided by financing activities | 15 | 15 |
| (decrease)/increase in cash and cash equivalents | -39,623 | -80,021 |
| Cash and cash equivalents at beginning of period | 121,330 | - |
| Effect of exchange rate changes on cash | 324 | - |
| Cash and cash equivalents at end of period | 82,031 | - |
Silence Therapeutics plc (SLN)
Silence Therapeutics plc (SLN)